Florida Department of Health

The council reviewed and discussed proposed rule language concerning equipment and devices, specifically protocols for laser and light-based devices. Key topics included addressing concerns from the Board of Medicine regarding the direct supervision and responsibility of physicians, debating the necessity of a mileage radius restriction for telehealth, and considering a proposal to require supervising physicians to be located within the state of Florida. The council voted to approve the amended rule language and concluded that the rule would not have an adverse economic impact on small businesses or government entities.

The committee reviewed and approved several new research studies, including the Multicenter AIDS Cohort Study, Childhood Cancer Survivor Study Linkage, The Florida Cohort study, Five Point Initiative trial, and research on maternal care access and safety of therapeutics in pregnancy. Administrative business included the consolidation of committee members into one group, the ongoing development of member training materials, and status updates on CITI certifications and outstanding review assignments. The board also reviewed numerous continuing projects and acknowledged the closure of several other studies.

The committee meeting covered program updates, including statistics on referrals and client enrollment, and showcased several success stories from different regions featuring clients with traumatic brain and spinal cord injuries. Additionally, the committee reviewed Google Analytics data regarding website traffic, discussed trends in client services, and hosted a guest speaker from the University of Miami who presented on brain-computer interface neuromodulation approaches for motor function recovery.

The meeting was convened for the IRB 2 committee; however, a quorum was not present. Consequently, no official actions were taken, and no educational activities occurred during the session.

The committee held an educational session regarding data registry types, sources, confidentiality, and related misconceptions. Regarding protocol reviews, the committee approved a modification to the REPRIEVE A5332 study, which involved an increase in participant compensation. Additionally, the committee reviewed the Egrifta Long Term Observational Study, involving changes in principal investigator and research coordinator personnel, and requested further information regarding FDA recommendations on the study's continuation due to low enrollment.